Curium-244 ion (Cm-244) (Cm-244)

Curium-244 is a synthetic radioactive isotope of the actinide series, primarily produced in nuclear reactors and characterized as a potent alpha-particle emitter with a physical half-life of approximately 18.1 years (NRC, 2021). It is not a physiological target or receptor; instead, it is a significant radiological contaminant and toxicant. Upon internalization via inhalation or ingestion, curium ions are absorbed into the bloodstream and preferentially deposit on bone surfaces and in the liver, where they remain for long periods due to their slow biological clearance (EPA, 2023). The high-energy alpha radiation emitted by curium-244 causes dense ionization along its path, resulting in severe DNA damage, such as double-strand breaks, and increasing the lifetime risk of developing osteosarcoma, leukemia, and liver disease (CDC, 2018). Pharmacological intervention is limited to decorporation therapy, where chelating agents such as diethylenetriaminepentaacetic acid (DTPA) are administered to bind the curium ions, forming stable, water-soluble complexes that are subsequently excreted by the kidneys (FDA, 2004).

Other names

Cm-244Curium-244244Cm

Chelation therapy involves the use of ligands like DTPA to form stable, soluble complexes with curium ions, facilitating their renal excretion and reducing the radiation dose to internal organs.